WO2023166796A1 - Composition d'huile essentielle - Google Patents

Composition d'huile essentielle Download PDF

Info

Publication number
WO2023166796A1
WO2023166796A1 PCT/JP2022/043319 JP2022043319W WO2023166796A1 WO 2023166796 A1 WO2023166796 A1 WO 2023166796A1 JP 2022043319 W JP2022043319 W JP 2022043319W WO 2023166796 A1 WO2023166796 A1 WO 2023166796A1
Authority
WO
WIPO (PCT)
Prior art keywords
oil
mass
composition
medium
essential
Prior art date
Application number
PCT/JP2022/043319
Other languages
English (en)
Japanese (ja)
Inventor
利彦 岡野
研之 服部
Original Assignee
学校法人 明治薬科大学
カラーズ株式会社
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 学校法人 明治薬科大学, カラーズ株式会社 filed Critical 学校法人 明治薬科大学
Priority to JP2023540778A priority Critical patent/JP7436975B2/ja
Publication of WO2023166796A1 publication Critical patent/WO2023166796A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
    • A23L2/52—Adding ingredients
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/13—Coniferophyta (gymnosperms)
    • A61K36/15—Pinaceae (Pine family), e.g. pine or cedar
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A61K36/534—Mentha (mint)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/75—Rutaceae (Rue family)
    • A61K36/752—Citrus, e.g. lime, orange or lemon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783—Angiosperms [Magnoliophyta]
    • A61K8/9789—Magnoliopsida [dicotyledons]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P60/00—Technologies relating to agriculture, livestock or agroalimentary industries
    • Y02P60/80—Food processing, e.g. use of renewable energies or variable speed drives in handling, conveying or stacking
    • Y02P60/87—Re-use of by-products of food processing for fodder production

Definitions

  • the present invention relates to a composition and the like for suppressing activation of microglial cells.
  • Microglial cells are small, non-neuronal stromal cells of mesodermal origin that form part of the supporting tissue of the central nervous system. Normally, microglial cells have multiple elongated branching processes called laminid type. When stimuli such as nerve cell injury are applied, microglial cells are activated and morphologically change to amoeba-like ameboids. In recent years, activation of microglial cells in the brain can cause depression, schizophrenia, dementia, Alzheimer's disease, Parkinson's disease, multiple sclerosis, lateral sclerosis, and Huntington's disease. It is known that activation of microglial cells in the spinal cord can cause chronic fatigue syndrome.
  • Essential oils refer to oils containing volatile aromatic components that are mainly extracted from plants, and are used as aromatherapy, fragrances, and skin emollients, as well as anti-inflammatory and antibacterial effects. reported to have It has also been reported that some essential oil components migrate into the brain when volatilized essential oils are inhaled. However, the relationship between essential oils and microglial cells, particularly the effect of essential oils on the activation of microglial cells, has not been investigated.
  • One of the objects of the present invention is to provide compositions such as foods, drinks, cosmetics, etc. for suppressing the activation of microglial cells.
  • One of the objects of the present invention is to provide compositions for inhibiting the release of IL-1 ⁇ .
  • One of the objects of the present invention is to provide a pharmaceutical composition for suppressing inflammation caused by activation of microglial cells.
  • One of the objects of the present invention is to provide a pharmaceutical composition for treating or preventing neurological diseases caused by activation of microglial cells.
  • the present inventors have discovered that a specific essential oil has an effect of suppressing the activation of microglial cells and/or an effect of suppressing the release of IL-1 ⁇ , leading to the present invention. More specifically, the present invention can have the following aspects.
  • 1 essential oil selected from the group consisting of citrus medica vulgaris pericarp oil, cypress oil, lemon pericarp oil, lime oil, red pine leaf oil, Roman chamomile flower oil, spearmint oil, and ylang-ylang flower oil
  • a composition for inhibiting activation of microglial cells comprising more than one species.
  • the essential oil is one or more essential oils selected from the group consisting of cypress oil and Roman chamomile flower oil.
  • composition according to [1] or [2] above wherein the content of the essential oil is 0.001 to 30% by mass when the composition is 100% by mass.
  • composition according to any one of [1] to [3] above wherein the composition is a pharmaceutical composition, food or drink, cosmetics, animal feed, or miscellaneous goods.
  • composition according to any one of [1] to [3] above which is a pharmaceutical composition for suppressing inflammation caused by activation of microglial cells.
  • the suppression of inflammation is accompanied by suppression of the release of pro-inflammatory cytokines selected from IL-1 ⁇ , IL-1 ⁇ , IL-6, IFN- ⁇ , MCP-1 and TNF- ⁇ ;
  • pro-inflammatory cytokines selected from IL-1 ⁇ , IL-1 ⁇ , IL-6, IFN- ⁇ , MCP-1 and TNF- ⁇ ; The composition according to [5] above.
  • the neurological disease is selected from depression, schizophrenia, dementia, Alzheimer's disease, Parkinson's disease, multiple sclerosis, lateral sclerosis, Huntington's chorea, and chronic fatigue syndrome, [8 ] The pharmaceutical composition as described in ].
  • the essential oil is one or more essential oils selected from the group consisting of Nelumbo japonicum oil and Roman chamomile flower oil.
  • the present invention it is possible to provide an effect of suppressing activation of microglial cells and/or an effect of suppressing release of IL-1 ⁇ . Moreover, according to the present invention, it is possible to provide an effect of suppressing inflammation caused by activation of microglial cells and an effect of treating or preventing neurological diseases caused by activation of microglial cells.
  • compositions comprising a particular essential oil.
  • the composition is not limited to forms such as solution, gel, solid, and mist as long as it is the essential oil itself or a mixture containing the essential oil.
  • Compositions may be not only pharmaceutical compositions and formulations, but also food and drink, cosmetics, animal feeds, miscellaneous goods, etc., and existing pharmaceutical compositions, food and drink, and cosmetics using the composition as a raw material. , animal feed, miscellaneous goods, and the like.
  • An essential oil means an oil obtained mainly by extraction from plants, preferably an oil containing volatile aromatic components.
  • Essential oils include animal-derived essential oils and plant-derived essential oils, and plant-derived essential oils are preferred in the present invention.
  • the essential oil is preferably liquid at room temperature (25°C ⁇ 5°C).
  • essential oils with high volatility are preferable because the active ingredients in the essential oils can be taken into the body by inhalation as in the case of using an aroma diffuser, and they are a simple administration form.
  • the part of the plant from which the essential oil is extracted is not particularly limited, but examples include leaves, roots, stems, bark, seeds, flowers, fruits, fruit peels, and combinations thereof. The plant can be used as it is or after drying and crushing the plant.
  • the essential oils that can be used as active ingredients in the present invention include Citrus medica vulgaris pericarp oil, Pyrrhiza medicinalis oil, Lemon pericarp oil, Lime oil, Scots pine leaf oil, Roman chamomile flower oil, spearmint oil, and ylang-ylang flower oil. one or more essential oils selected from the group;
  • Citrus medica vulgaris pericarp oil refers to oil containing aromatic components obtained by extraction from the pericarp of Citrus medica vulgaris.
  • the oil of Nyukoju is an oil containing aromatic components obtained by extracting a part or the whole of Nyukoju, including the wood, bark or sap of Nyukoju.
  • Lemon peel oil refers to oil containing aromatic components obtained by extraction from lemon peel.
  • Lime oil refers to oil containing aromatic components obtained by extracting a part or the whole of lime, including lime fruit, peel or pulp.
  • Scots pine leaf oil refers to oil containing aromatic components obtained by extracting from the leaves of Scots pine.
  • Roman chamomile flower oil refers to oil containing aromatic components obtained by extraction from Roman chamomile flowers.
  • Spearmint oil refers to oil containing aromatic components obtained by extracting a part or the whole of spearmint including leaves, stems, roots, etc. of spearmint.
  • Ylang-ylang flower oil refers to oil containing aromatic components obtained by extracting from ylang-ylang flowers. A preferred extraction method will be described later.
  • These essential oils were specifically found to have remarkable effects such as suppression of activation of microglial cells, and are preferred. This effect is surprising given that bergamot fruit oil, mint leaf oil and eucalyptus leaf oil, which are similar to these essential oils, do not exhibit this effect.
  • These essential oils that can be used as active ingredients in the present invention may be used alone or in combination of two or more. When two types of essential oils are used in combination, the mass ratio is, for example, 99:1 to 1:99, preferably 9:1 to 1:9, more preferably 5:1 to 1:5, still more preferably 2:1. ⁇ 1:2 is suitable.
  • the content of the essential oil in the composition of the present invention is, when the composition is 100% by mass, for example, 0.001 to 30% by mass, preferably 0.01 to 20% by mass, more preferably 0.01 to 10% by mass, more preferably 0.1 to 10% by mass.
  • the content of the essential oil in the composition of the present invention is, for example, 0.001 to 30% by mass, preferably 0.01 to 20% by mass, more preferably It is suitably 0.01 to 10% by mass, more preferably 0.1 to 10% by mass.
  • the content of the essential oil varies depending on the form of the composition. may be 30 to 100% by mass, 70 to 100% by mass, or 95 to 98% by mass.
  • the composition of the present invention may contain other essential oils and other active ingredients in addition to the above essential oils as active ingredients. Although other essential oils cannot be expected to have the action and effect of the present invention, other relaxing effects, moisturizing effects, and the like can be obtained.
  • Other essential oils include yuzu peel oil, bergamot leaf oil, bergamot fruit oil, damask rose flower oil, shouzuku seed oil, coccineum oil, chamomile flower oil, salvia oil, eucalyptus leaf oil, sycamore oil, ginger root oil.
  • active ingredients are the effect of the present invention such as the effect of suppressing the activation of microglial cells and the effect of suppressing the release of IL-1 ⁇ , and other effects such as antibacterial, insecticidal, anti-inflammatory.
  • active ingredients include, for example, ⁇ -lactam antibacterial agents, fosfomycin, vancomycin, minocycline, ciclesonide, and the like.
  • the content of other active ingredients in the composition can be added in any amount as long as it is an amount that does not impair the effect of the original active ingredient (essential oil). It is suitable to contain 90 mass %, preferably 0.01 mass % to 70 mass %, more preferably 0.1 mass % to 50 mass %.
  • composition of the present invention may optionally contain excipients, binders, emulsifiers, solvents, adhesives, disintegrants, thickeners, lubricants, colorants, Additives such as flow agents and moisturizing agents may be added.
  • excipients include alcohol, glycerin, dextrin, starch and the like.
  • Binders can include, for example, cellulose, methylcellulose, hydroxyethylcellulose, and sodium carboxymethylcellulose.
  • emulsifiers include lecithin, polyethylene glycol (PG), glycerin fatty acid ester, sorbitan fatty acid ester, propylene glycol fatty acid ester, sucrose fatty acid ester and the like.
  • Solvents include, for example, monohydric or polyhydric alcohols such as methanol, ethanol, propanol, n-butanol, ethylene glycol, propylene glycol, dipropylene glycol; ketones such as acetone and methyl ethyl ketone; diethyl ether, tetrahydrofuran (THF ); organic solvents such as hexane, benzene, toluene, chloroform, dichloromethane, and dimethylformamide; avocado oil, camellia oil, turtle oil, macadamia nut oil, corn oil, mink oil, olive oil, rapeseed oil, egg yolk oil, sesame oil , persic oil, wheat germ oil, sasanqua oil, castor oil, linseed oil, safflower oil, cottonseed oil, perilla oil, soybean oil, peanut oil, tea seed oil, kaya oil, rice bran oil, linagiri oil, Japanese paul
  • Preferred solvents include ethanol, olive oil, squalane, myristyl myristate and water. These additives can be used singly or in combination of two or more. Those that act as both excipients and solvents, such as alcohols, act as both excipient and solvent additives even when one is included.
  • the content of the additive in the composition can be added in any amount as long as it is an amount that does not impair the effect of the active ingredient. It is suitable to contain from 0.1% to 30% by mass, more preferably from 0.1% by mass to 50% by mass.
  • the organic solvent is, for example, 1% by mass to 99.9% by mass, preferably 1% by mass to 99% by mass, more preferably about 20% by mass to 90% by mass. It is appropriate to contain
  • the oil content is, for example, 0.01 to 95% by mass, preferably 1 to 90% by mass, more preferably 5 to 80% by mass.
  • a method for producing an essential oil a method generally used for preparing an essential oil can be used, and a method generally known as a method of extracting a plant to obtain an essential oil can be used.
  • the extraction method for example, pressing, squeezing, solvent extraction, steam distillation, supercritical extraction, carbon dioxide gas extraction, cold immersion method, digestion method, etc. can be used alone or in combination.
  • the essential oil can be obtained by optionally removing the solvent and the like from the liquid extract obtained by these extraction methods.
  • extraction solvents include monohydric or polyhydric alcohols such as methanol, ethanol, propanol, n-butanol, ethylene glycol, propylene glycol; ketones such as acetone and methyl ethyl ketone; diethyl ether, tetrahydrofuran (THF) and the like. ethers; organic solvents such as hexane, benzene, toluene, chloroform, dichloromethane and dimethylformamide; and water.
  • the extraction conditions for extraction vary depending on the plant and solvent used, but the temperature, pressure, extraction time, etc. generally used in extraction methods can be used.
  • the steam distillation method using steam at a temperature of 40 to 120 ° C., preferably 50 to 100 ° C. below the boiling point of general essential oils (150 to 350 ° C.), for example, 5 to 200 kPa, preferably 10 to 100 kPa may be carried out under a reduced pressure of
  • the extraction method using an alcohol such as ethanol may be carried out at room temperature (25° C. ⁇ 5° C.) under high pressure of 300 to 1000 kPa, preferably about 500 to 800 kPa.
  • the extraction solvent may be removed after the extraction operation.
  • compositions of the present invention can be used not only in pharmaceutical compositions, but also in foods and beverages, cosmetics, animal feeds, and miscellaneous goods.
  • Pharmaceutical compositions include, for example, oral administration agents such as tablets, pills, capsules, powders, granules, syrups, and sublingual agents; injections (intravenous injection, intramuscular injection, local injection, etc.), gargles, Parenteral administration agents such as drops, external agents (ointments, creams, poultices, patches, inhalants), and suppositories can be mentioned.
  • Food and drink products include beverages and foods, and examples of beverages include tea, coffee, soft drinks, fruit juice drinks, carbonated drinks, sports drinks, non-alcoholic drinks, and alcoholic drinks.
  • Foods in general given to humans such as plant foods, animal foods, synthetic foods, cereals, bread, noodles, cakes, noodles, freeze-dried foods, dairy products, seasonings, frozen foods, nutritional supplements , and medical foods.
  • cosmetics include lotions, milky lotions, moisturizers, serums, skin oils, perfumes, sunscreens, shaving lotions, packs, hair tonics, hair balms, hair waxes, hair greases, hair oils, hair treatments, hair colors, and face washes.
  • cosmetics body shampoos, shampoos, rinses, conditioners, cleansers, creams, body creams, hand creams, makeup bases, foundations, mascara, eyeliners, concealers, lipsticks, lip balms, glosses and nail colors.
  • Animal feeds include, for example, feeds for animals such as dogs, cats, horses, sheep, pigs, monkeys, rabbits, guinea pigs, mice, birds, chickens, ducks, and goats, especially mammals.
  • miscellaneous goods include aromatics, aroma diffusers, aroma candles, aroma stones, aroma mists, clothing mists, deodorant mists, pillow mists, insect repellents, clothing detergents, softeners, and bath agents.
  • the content of the composition depends on the type of pharmaceutical composition, etc., but is an amount that does not impair the effects of the present invention.
  • 0.001% to 70% by mass preferably 0.01% to 50% by mass, more preferably 0.1% to 30% by mass with respect to the total amount
  • animal feeds it is suitable to contain, for example, 0.001% to 50% by mass, preferably 0.01% to 30% by mass, more preferably 0.1% to 10% by mass.
  • miscellaneous goods it is suitable to contain, for example, 0.01% by mass to 100% by mass, preferably 0.01% by mass to 80% by mass, more preferably 0.1% by mass to 50% by mass.
  • the composition of the present invention is used to suppress activation of microglial cells (Method for Suppressing Microglial Cell Activation).
  • Microglial cells are small, non-neuronal stromal cells of mesodermal origin that form part of the supporting tissue of the central nervous system.
  • Essential oils are generally known to have anti-inflammatory effects, but they are not known to have the effect of suppressing the activation of microglial cells. was found to be effective. It is surprising to see such an effect, and it is expected that diseases and conditions caused by activation of microglial cells can be alleviated and cured.
  • the composition of the present invention can also be used to treat or prevent neurological diseases caused by activation of microglial cells (method for treating or preventing neurological diseases caused by activation of microglial cells).
  • neurological diseases include depression, schizophrenia, dementia, Alzheimer's disease, Parkinson's disease, multiple sclerosis, lateral sclerosis, Huntington's disease, chronic fatigue syndrome, and the like.
  • the composition of the present invention is also used to inhibit the release of IL-1 ⁇ (IL-1 ⁇ release inhibition method). In particular, it was found that by using the specific essential oil of the present invention, an IL-1 ⁇ production inhibitory effect can be obtained without showing substantial or significant cytotoxicity.
  • the composition of the present invention is also used to suppress inflammation caused by activation of microglial cells (method for suppressing inflammation caused by activation of microglial cells). Inflammation here mainly includes inflammation in the brain and spinal cord. Examples of intracerebral sites where inflammation occurs include hippocampus, cerebral cortex, cerebellum, basal ganglia, and nigrostriatum. The spinal cord site where inflammation occurs includes the dorsal horn of the spinal cord and the like.
  • the inflammation is, for example, an inflammation selected from IL-1 ⁇ , IL-1 ⁇ , IL-2, IL-6, IL-12, IL-17, IL-18, IFN- ⁇ , MCP-1 and TNF- ⁇ Expression of an inducible cytokine, preferably with release (expression) of a pro-inflammatory cytokine selected from IL-1 ⁇ , IL-1 ⁇ , IFN- ⁇ , MCP-1 and TNF- ⁇ .
  • a pro-inflammatory cytokine selected from IL-1 ⁇ , IL-1 ⁇ , IFN- ⁇ , MCP-1 and TNF- ⁇ .
  • the composition of the present invention particularly the specific essential oil as an active ingredient, suppresses the release (expression) of pro-inflammatory cytokines such as IL-1 ⁇ , thereby suppressing the activation of microglial cells.
  • microglial cells include MG6 cells, iCell (R) microglia, and BV2 cells.
  • composition of the present invention is in the form of a pharmaceutical composition or food (especially functional food or dietary supplement), it varies depending on the dosage form, administration subject, administration route, target disease, symptom, active ingredient concentration, etc.
  • the dosage of the active ingredient per day is, for example, 0.1 to 20 mg/kg body weight, preferably 0.2 to 10 mg/kg body weight, more preferably 0.5 to 10 mg/kg body weight. , it is desirable to administer this amount once to several times a day (eg, 2, 3, 4 or 8 times).
  • the amount is, for example, 0.1 to 20 mg/day, preferably 0.2 to 10 mg/day, more preferably 0.5 to 10 mg/day. is appropriate.
  • the administration method varies depending on the dosage form and form of the pharmaceutical composition or food. For example, when a liquid agent is administered to a subject by inhalation, it is preferably administered by an aroma diffuser, a spray, a mist, or the like.
  • Example 1 [Preparation of composition] As each essential oil, the essential oils listed in Table 2 were used. A composition of each essential oil was prepared as a 10% (w/w) ethanol solution by weighing 2-3 mg of each essential oil and adding 9 volumes (w/w) of ethanol.
  • Comparative Example 1 [Preparation of composition] The essential oils listed in Table 3 were used as comparative essential oils. As in Example 1, 2-3 mg of the essential oil was weighed and 9 times the amount (w/w) of ethanol was added to prepare each composition as a 10% (w/w) ethanol solution.
  • MG6 cells a mouse-derived microglial cell line, were purchased from the RIKEN Cell Bank (cell number RCB2403).
  • the medium used for culture was D-MEM (manufactured by Fujifilm Wako, product number; 049-32645) 500mL, fetal bovine serum (manufactured by Biofill) 50mL was added, and insulin (Fujifilm Wako Pure Chemical Co., Ltd. 099-06473) and 2-mercaptoethanol at final concentrations of 10 ⁇ g/mL and 0.1 mmol/L, respectively (hereinafter referred to as medium A).
  • MG6 cells were cultured according to the method specified by Riken's cell bank.
  • MG6 cells were seeded in a 24-well plate at 0.5 ⁇ 10 5 cells/well, and the next day, the adherence of the cells was confirmed. , performed the following: First, medium 1 was prepared by adding LPS (manufactured by Fujifilm Wako Pure Chemical Industries, Ltd., product number: 125-05181) to medium A at a final concentration of 1 ⁇ g/mL.
  • LPS manufactured by Fujifilm Wako Pure Chemical Industries, Ltd., product number: 125-05181
  • medium 2 was prepared by adding ATP (manufactured by Fuji Film Wako Pure Chemical Industries, Ltd., product number: 303-50511) to a new medium A in such an amount that the final concentration was 1 mmol/L. After removing the medium from each well, 0.5 mL/well of medium 1 was added to the MG6 cells cultured in the 24-well plate prepared as described above, and cultured for 4 hours. Next, the medium in each well was removed, 0.5 mL/well of medium 2 was added to each well of MG6 cells, and the cells were cultured for 30 minutes.
  • ATP manufactured by Fuji Film Wako Pure Chemical Industries, Ltd., product number: 303-50511
  • the medium was collected from each well as a medium for measuring activation, and a solution prepared by adding 0.1% Triton X-100 (manufactured by Nacalai Tesque) to the new medium A was prepared. , 0.5 mL/well was added to each well to prepare a cell lysate containing MG6 cells.
  • medium 3 or medium 3 prepared in the same manner as medium 1 or medium 2, except that LPS or ATP was added at a final concentration twice that of medium 1 and medium 2, respectively.
  • Medium 4 was prepared.
  • 10 ⁇ L of each composition (10% (w/w) ethanol solution of essential oil) prepared in Example 1 and Comparative Example 1 was aliquoted and added to 5 mL of Medium A. After that, it was suspended using an ultrasonic homogenizer (manufactured by Branson, product number: SFX150) to obtain medium 5.
  • an ultrasonic homogenizer manufactured by Branson, product number: SFX150
  • MG6 cells were seeded in a 24-well plate at 0.5 ⁇ 10 5 cells/well in the same manner as in the previous [Method for activating microglia with LPS and ATP using MG6 cells].
  • MG6 cells cultured on a 24-well plate were prepared. After removing the medium from each well of the MG6 cells cultured on the prepared 24-well plate, 0.5 mL/well of medium 6 was added to each well, and the MG6 cells were cultured for 4 hours. Next, after removing the medium from each well, 0.5 mL/well of medium 7 was added to each well, and the MG6 cells were further cultured for 30 minutes.
  • the medium was collected from each well as a medium for measuring activation, and a solution prepared by adding 0.1% Triton X-100 (manufactured by Nacalai Tesque) to the new medium A was prepared. , 0.5 mL/well was added to each well to prepare a cell lysate containing MG6 cells.
  • MCC950 is an inhibitor of NLRP3 inflammasome, MCC950 (Funakoshi Co., Ltd., product number: AG-CR1-3615-M001), added to medium 1 and medium 2 to a final concentration of 10 ⁇ mol / L. It was used as a positive control to confirm that IL-1 ⁇ release was actually suppressed.
  • the IL-1 ⁇ concentrations in Tables 4-1 to 4-5 are average values measured three times.
  • the cytotoxicity rate was measured by LDH assay.
  • LDH assay kit product number: 341-91754 manufactured by Fuji Film Wako Pure Chemical Industries, Ltd.
  • the total LDH activity in the medium for activation measurement in each well and the cell lysate was defined as the total LDH activity, and the ratio of the LDH activity in the cell lysate to the total LDH activity was expressed as a cytotoxicity rate in %.
  • control and MCC950 used are the same as in Tables 4-1 to 4-5.
  • essential oils that do not show a significant increase in the cytotoxicity rate compared to the control, those that suppress the release of IL-1 ⁇ into the medium are particularly effective in suppressing the activation of MG6 cells. I assumed.
  • the cytotoxicity rates in Tables 5-1 to 5-5 are the average values measured three times.
  • iCell (R) microglia [IL-1 ⁇ release inhibition test for iCell (R) microglia] ⁇ Preparation of cell lysate containing human iPS cell-derived microglial cells and no essential oil (for control) As microglial cells, iCell (R) microglia (manufactured by FUJIFILM Cellular Dynamics, Inc.), which are human iPS cell-derived microglial cells, were used. Note that iCell is a registered trademark of Fujifilm Cellular Dynamics Inc. iCell (R) microglia were cultured according to the culture method recommended by Fujifilm Wako Pure Chemical Industries, Ltd.
  • iCell (R) microglial basal medium manufactured by Fujifilm Wako Pure Chemical Industries, Ltd., product number: 556-36861
  • iCell (R) microglial supplement A product number: 550-36881
  • Microglial supplement B product number: 557-36891
  • iCell (R) nerve supplement C product number: 553-36871
  • medium B medium
  • the adhesiveness of iCell (R) microglia is weak, the culture vessel was coated with Cell-Tak cell and tissue adhesive (Cell-Tak, manufactured by Corning, product number: CLS354240) during the culture.
  • the iCell (R) microglia were suspended in the medium B at 1 ⁇ 10 5 cells/mL, and seeded onto a 48-well plate at 0.25 mL/well. After seeding, centrifugation was performed at 20°C and 1,000 rpm for 5 minutes using a Tomy centrifuge (part number: CAX-571) and a rotor (part number: TS-4C) to spread the cells to the bottom of the plate. Collected to promote adhesion. Two days after seeding, the medium was removed, and medium 8 obtained by adding LPS (manufactured by Fujifilm Wako Pure Chemical Industries, Ltd., product number: 125-05181) at a final concentration of 1 ⁇ g/mL to the new medium B was added to each well.
  • LPS manufactured by Fujifilm Wako Pure Chemical Industries, Ltd., product number: 125-05181
  • iCell (R) microglia were cultured for 4 hours.
  • the medium 8 was removed from each well, and ATP (manufactured by Fuji Film Wako Pure Chemical Industries, Ltd., product number: 303-50511) was added to the new culture medium B so that the final concentration was 1 mmol/L.
  • 0.25 mL/well of medium 9 was added and the iCell (R) microglia were further cultured for 30 minutes.
  • the medium After culturing for 30 minutes, the medium is collected from each well as a medium for measuring activation, and the remaining iCell (R) microglia is added to 10 mL of medium B as a medium for MTT assay (manufactured by Dojindo Laboratories, product number: 0.25 mL/well of a mixed solution containing 1 mL of CK04) was added to each well and cultured for 4 hours. The culture medium after culturing for 4 hours was used as a cell viability measurement medium.
  • MTT assay manufactured by Dojindo Laboratories, product number: 0.25 mL/well of a mixed solution containing 1 mL of CK04
  • medium 10 or medium 10 prepared in the same manner as medium 8 or medium 9, except that LPS or ATP was added at a final concentration twice that of medium 8 or medium 9, respectively.
  • a medium 11 was prepared.
  • 10 ⁇ L of each composition (10% (w/w) ethanol solution of essential oil) prepared in Example 1 and Comparative Example 1 above was aliquoted and added to 5 mL of Medium B above. After that, it was suspended using an ultrasonic homogenizer (manufactured by Branson, product number: SFX150) to obtain medium 12. 3 mL each of this medium 12 and medium 10 or medium 11 were mixed to adjust the final concentration of each essential oil in the culture medium containing LPS or ATP to 100 ppm, which was designated as medium 13 or 14, respectively.
  • iCell (R) microglia were suspended in the above medium B to a concentration of 1 x 10 5 cells/mL, and 0.0. Seeded at 25 mL/well. After removing the medium from each well of iCell (R) microglial cells cultured on the 48-well plate, 0.25 mL/well of medium 13 was added to each well, and MG6 cells were cultured for 4 hours.
  • MTT reagent manufactured by Dojindo Laboratories, product number: 0.25 mL/well of a mixed solution containing 1 mL of CK04 was added to each well and cultured for 4 hours. The culture medium after culturing for 4 hours is used as the cell viability measurement medium.
  • MTT assay ⁇ Measurement of absorbance
  • the relative absorbance value (%) of each addition group was defined as the survival rate.
  • the effect of suppressing the activation of microglial cells derived from human iPS cells was excellent.
  • the cytotoxicity rate in Table 6 is the average value measured three times.
  • Formulation Example 1 [Aroma Diffuser Oil 1] Nyukoju oil (FRANKINCENSE OIL, Boswellia Carterii Oil, Cas RN (R) : 89957-98-2): 30% by mass ethanol: residue

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Botany (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Medical Informatics (AREA)
  • Psychiatry (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Psychology (AREA)
  • Birds (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

Le but de la présente invention est de fournir, par exemple, une composition pour supprimer l'activation de cellules microgliales. Plus particulièrement, la présente invention concerne, par exemple, une composition qui est destinée à supprimer l'activation de cellules microgliales et qui comprend une ou plusieurs huiles essentielles choisies dans le groupe constitué par l'huile de pelage de Citrus medica vulgaris, l'huile de Boswellia Carterii, l'huile de zeste de citron, l'huile de citron vert, l'huile de feuilles de Pinus sylvestris, l'huile de fleur d'Anthemis nobilis, l'huile de menthe verte et l'huile de fleur de ylang-ylang.
PCT/JP2022/043319 2022-03-03 2022-11-24 Composition d'huile essentielle WO2023166796A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023540778A JP7436975B2 (ja) 2022-03-03 2022-11-24 精油組成物

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2022-032704 2022-03-03
JP2022032704 2022-03-03

Publications (1)

Publication Number Publication Date
WO2023166796A1 true WO2023166796A1 (fr) 2023-09-07

Family

ID=87883609

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2022/043319 WO2023166796A1 (fr) 2022-03-03 2022-11-24 Composition d'huile essentielle

Country Status (2)

Country Link
JP (1) JP7436975B2 (fr)
WO (1) WO2023166796A1 (fr)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010132629A (ja) * 2008-12-03 2010-06-17 Triple Act:Kk 皮膚外用組成物
JP2017533960A (ja) * 2014-10-31 2017-11-16 ポメガ インク ザクロ種子油、ｒｏｓａ ｃａｎｉｎａ果実油、およびｉｎｕｌａ ｖｉｓｃｏｓａ含油樹脂または抽出物を含有する製剤

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010132629A (ja) * 2008-12-03 2010-06-17 Triple Act:Kk 皮膚外用組成物
JP2017533960A (ja) * 2014-10-31 2017-11-16 ポメガ インク ザクロ種子油、ｒｏｓａ ｃａｎｉｎａ果実油、およびｉｎｕｌａ ｖｉｓｃｏｓａ含油樹脂または抽出物を含有する製剤

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CASETTI FEDERICA, RAFEI‐SHAMSABADI DAVID, MÜLLER SABINE: "‐anaphylaxis after subcutaneous injection of mistletoe extract", CONTACT DERMATITIS: ENVIRONMENTAL AND OCCUPATIONAL DERMATITIS, WILEY-BLACKWELL PUBLISHING, INC., US, vol. 85, no. 4, 1 October 2021 (2021-10-01), US , pages 462 - 465, XP093088449, ISSN: 0105-1873, DOI: 10.1111/cod.13880 *
CHEN JIALI, TANG CAILIN, ZHOU YANG, ZHANG RONGFEI, YE SHAOXIA, ZHAO ZHIMIN, LIN LIGEN, YANG DEPO: "Anti-Inflammatory Property of the Essential Oil from Cinnamomum camphora (Linn.) Presl Leaves and the Evaluation of Its Underlying Mechanism by Using Metabolomics Analysis", MOLECULES, vol. 25, no. 20, 19 October 2020 (2020-10-19), pages 4796, XP093088446, DOI: 10.3390/molecules25204796 *
GYÖRGYI HORVÁTH; ADRIENN HORVÁTH; GRÉTA REICHERT; ANDREA BÖSZÖRMÉNYI; KATALIN SIPOS; EDINA PANDUR: "Three chemotypes of thyme (Thymus vulgaris L.) essential oil and their main compounds affect differently the IL-6 and TNFα cytokine secretions of BV-2 microglia by modulating the NF-κB and C/EBPβ signalling pathways", BMC COMPLEMENTARY MEDICINE AND THERAPIES, BIOMED CENTRAL LTD, LONDON, UK, vol. 21, no. 1, 22 May 2021 (2021-05-22), London, UK , pages 1 - 14, XP021291293, DOI: 10.1186/s12906-021-03319-w *
XU MENGJIE, ZHANG XIAOYING, REN FANGYI, YAN TINGXU, WU BO, BI KAISHUN, BI WENCHUAN, JIA YING: "Essential oil of Schisandra chinensis ameliorates cognitive decline in mice by alleviating inflammation", FOOD & FUNCTION, R S C PUBLICATIONS, GB, vol. 10, no. 9, 18 September 2019 (2019-09-18), GB , pages 5827 - 5842, XP093088440, ISSN: 2042-6496, DOI: 10.1039/C9FO00058E *

Also Published As

Publication number Publication date
JPWO2023166796A1 (fr) 2023-09-07
JP7436975B2 (ja) 2024-02-22

Similar Documents

Publication Publication Date Title
KR101822874B1 (ko) 시계 유전자 Ｂｍａｌ의 발현 조절제
KR101770706B1 (ko) 시계 유전자 Ｐｅｒｉｏｄ의 발현 조절제
KR101922635B1 (ko) 마유 및 새싹 추출물을 함유하는 피부 염증 개선용 화장료 조성물
KR20180051821A (ko) 개망초꽃으로부터 추출된 에센셜 오일을 포함하는 피부재생용 조성물
JP5616045B2 (ja) セラミド産生促進剤及び保湿剤
EP2520304B1 (fr) Activateur de production de céramides et agent hydratant
KR101885000B1 (ko) 지칭개꽃으로부터 추출된 정유를 포함하는 피부재생용 조성물
JP5730550B2 (ja) Ｃｇｒｐ応答性促進剤
JP6843425B2 (ja) 幹細胞の未分化状態維持剤及び増殖促進剤
JP2014114235A (ja) メラニン産生抑制剤及びコラーゲン産生促進剤
JP7436975B2 (ja) 精油組成物
KR102411576B1 (ko) 잣나무 잎 추출물을 포함하는 항균 조성물
KR102085052B1 (ko) 식물 추출물을 포함하는 피부 항염 또는 피부 보습용 조성물
KR20160071005A (ko) 산국 에센셜 오일을 유효성분으로 함유하는 항산화 및 항비만 조성물
JP2014091721A (ja) セラミド産生促進剤
JP6026257B2 (ja) セラミド産生促進剤
JP2022006397A (ja) バリア機能亢進剤
JP6723979B2 (ja) しわ改善剤
KR20170058546A (ko) 주름개선용 화장료 조성물
JP6017259B2 (ja) エンドセリン作用抑制剤
JP6204019B2 (ja) Ｃｇｉ−５８発現促進剤
KR102329522B1 (ko) 골담초 꽃 오일을 포함하는 피부 재생 또는 주름개선용 조성물
KR20190033871A (ko) 피부 노화 개선 복합 화장료 조성물
JP6151027B2 (ja) セラミド産生促進剤
JP2024001415A (ja) プロスタグランジンｅ２産生抑制剤及び抗炎症剤

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 2023540778

Country of ref document: JP

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22929940

Country of ref document: EP

Kind code of ref document: A1